Dermapharm Holding SE (HAM:DMP) ROCE % : 18.01% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dermapharm Holding SE's annualized ROCE % for the quarter that ended in Mar. 2024 was 18.01%.

Dermapharm Holding SE ROCE % Historical Data

The historical data trend for Dermapharm Holding SE's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE ROCE % Chart

Dermapharm Holding SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

16.01

13.24

25.76

18.69

10.87

Dermapharm Holding SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															21.75	2.43	11.84	3.44	18.01

Dermapharm Holding SE ROCE % Calculation

Dermapharm Holding SE's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	160.965	/	( ( (1412.836 - 217.792)	+	(2160.673 - 394.489) )	/ 2 )
	=	160.965	/	( (1195.044	+	1766.184)	/ 2 )
	=	160.965	/	1480.614
	=	10.87 %

Dermapharm Holding SE's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	317.4	/	( ( (2160.673 - 394.489)	+	(2172.986 - 414.271) )	/ 2 )
	=	317.4	/	( ( 1766.184	+	1758.715 )	/ 2 )
	=	317.4	/	1762.4495
	=	18.01 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Dermapharm Holding SE (HAM:DMP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dermapharm Holding SE ROCE % Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Dermapharm Holding SE (HAM:DMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (HAM:DMP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0A5J:UK DMP:Germany

Address

Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031

Website

https://www.dermapharm.de

Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs and natural remedies. Its portfolio of products includes cosmetics, nutritional supplements and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals and cosmetics products. Parallel import brands business operates under the AxiCorp brand.

Dermapharm Holding SE (HAM:DMP) Headlines

No Headlines